ADMA Biologics Inc (ADMA)

NASDAQ:ADMA

ADMA

ADMA Biologics

RESEARCH TOOLSreports

Want to see ADMA full AI Analyst Report?

ADMA Biologics (ADMA) Price & Analysis

3,029 Followers

ADMA Stock Chart & Stats

$11.01

-$0.24(-1.31%)

At close: Jan 08 4:00 PM EST

$11.01

-$0.24(-1.31%)

Day’s Range― - ―

52-Week Range$7.21 - $22.37

Previous CloseN/A

Volume407.39K

Average Volume (3M)6.87M

Market Cap

$1.96B

Enterprise Value$1.98B

Total Cash (Recent Filing)$138.15M

Total Debt (Recent Filing)$204.41M

Price to Earnings (P/E)11.7

Beta0.94

Next Earnings

Aug 12, 2026

EPS Estimate

0.19

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.69

Shares Outstanding231,772,720

10 Day Avg. Volume7,901,107

30 Day Avg. Volume6,874,714

Financial Highlights & Ratios

PEG Ratio-1.09

Price to Book (P/B)9.11

Price to Sales (P/S)8.52

P/FCF Ratio156.23

Enterprise Value/Market Cap1.01

Enterprise Value/Revenue3.88

Enterprise Value/Gross Profit6.33

Enterprise Value/Ebitda9.29

Forecast

1Y Price Target

$23.67

Price Target Upside114.96% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering3

EPS Forecast (FY)0.84

Revenue Forecast (FY)$570.08M

Bulls Say, Bears Say

Bulls Say

Financial PerformanceADMA's underlying performance is strong, as evidenced by improved guidance for 2025 and 2026 following their earnings report.

Production OutputThe anticipated approval of Ig yield enhancement is expected to significantly increase production output, contributing to potential sales and margin growth.

Supply ChainThe recent long-term plasma contracts have alleviated supply concerns, supporting the growth potential for ASCENIV.

Bears Say

Regulatory FilingADMA stated it would be unable to file its 2024 10-K within the prescribed timeframe.

ADMA Biologics News

Adma Biologics price target lowered to $20 from $24 at Mizuho

Mizuho analyst Anthony Petrone lowered the firm’s price target on Adma Biologics (ADMA) to $20 from $24 and...

17d ago

ADMA

Adma Biologics price target lowered to $18 from $21 at Canaccord

Canaccord analyst Gary Nachman lowered the firm’s price target on Adma Biologics (ADMA) to $18 from $21 and...

17d ago

ADMA

Adma Biologics options imply 12.3% move in share price post-earnings

Pre-earnings options volume in Adma Biologics (ADMA) is 2.5x normal with calls leading puts 10:3. Implied volatility suggests...

17d ago

ADMA

Adma Biologics reports Q1 EPS 19c, consensus 20c

Reports Q1 revenue $114.49M, consensus $139.97M. “During the first quarter, the market for U.S. plasma derived therapies and...

17d ago

ADMA

Adma Biologics sees FY26 revenue $530M-$560M, consensus $629.1M

Sees FY26 adjusted EBITDA $265M-$300M. Grossman continued, “We believe the first quarter results likely represent a trough revenue...

17d ago

ADMA

Adma Biologics announces FDA approval for Asceniv sBLA

Adma Biologics (ADMA) announced the FDA has approved the company’s supplemental biologics license application submitted under section 351...

20d ago

ADMA

ADMA Biologics Earnings Call: ASCENIV Fuels Profits

ADMA Biologics Inc (($ADMA)) has held its Q1 earnings call. Read on for the main highlights of the...

16d ago

ADMA

Analyst Reaffirms Buy Rating on ADMA Biologics, Citing Expanded Asceniv FDA Label and Strong Growth Outlook Despite Bivigam Concerns

Canaccord Genuity analyst Gary Nachman maintained a Buy rating on ADMA Biologics today and set a price target...

19d ago

ADMA

ADMA Biologics Gains FDA Approval for Expanded ASCENIV Label

An announcement from ADMA Biologics ( ($ADMA) ) is now available. On May 4, 2026, ADMA Biologics announced...

20d ago

ADMA

ADMA Earnings this Week: How Will it Perform?

ADMA Biologics Inc (ADMA) is scheduled to report 1st quarter earnings on 05/06/2026, after the market closes. Regarding...

20d ago

ADMA

CrowdStrike, ADMA, Achieve, AbbVie, Valero Trending With Analysts

Analysts are intrested in these 5 stocks: ( ($CRWD) ), ( ($ADMA) ), ( ($ACHV) ), ( ($ABBV)...

29d ago

VLO

ABBV

Adma Biologics initiated with a Buy at Canaccord

Canaccord last night initiated coverage of Adma Biologics (ADMA) with a Buy rating and $21 price target The...

1M ago

ADMA

Adma Biologics initiated with a Buy at Canaccord

Canaccord initiated coverage of Adma Biologics (ADMA) with a Buy rating and $21 price target Published first on...

1M ago

ADMA

Adma Biologics price target lowered to $24 from $30 at Mizuho

Mizuho analyst Anthony Petrone lowered the firm’s price target on Adma Biologics (ADMA) to $24 from $30 and...

1M ago

ADMA

ADMA FAQ

What was ADMA Biologics Inc’s price range in the past 12 months?

ADMA Biologics Inc lowest stock price was $7.21 and its highest was $22.37 in the past 12 months.

What is ADMA Biologics Inc’s market cap?

ADMA Biologics Inc’s market cap is $1.96B.

When is ADMA Biologics Inc’s upcoming earnings report date?

ADMA Biologics Inc’s upcoming earnings report date is Aug 12, 2026 which is in 80 days.

How were ADMA Biologics Inc’s earnings last quarter?

ADMA Biologics Inc released its earnings results on May 06, 2026. The company reported $0.171 earnings per share for the quarter, missing the consensus estimate of $0.193 by -$0.022.

Is ADMA Biologics Inc overvalued?

According to Wall Street analysts ADMA Biologics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does ADMA Biologics Inc pay dividends?

ADMA Biologics Inc does not currently pay dividends.

What is ADMA Biologics Inc’s EPS estimate?

ADMA Biologics Inc’s EPS estimate is 0.19.

How many shares outstanding does ADMA Biologics Inc have?

ADMA Biologics Inc has 231,772,720 shares outstanding.

What happened to ADMA Biologics Inc’s price movement after its last earnings report?

ADMA Biologics Inc reported an EPS of $0.171 in its last earnings report, missing expectations of $0.193. Following the earnings report the stock price went down -15.972%.

Which hedge fund is a major shareholder of ADMA Biologics Inc?

Currently, no hedge funds are holding shares in ADMA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

ADMA Biologics Stock Smart Score

Neutral

Fundamentals

Return on Equity

38.97%

Trailing 12-Months

Asset Growth

30.28%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

ADMA Biologics (ADMA) Earnings & Revenues

Historic Earnings Reports

ADMA Earnings Call

Q1 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call conveyed materially positive operational and financial momentum driven by ASCENIV — including strong revenue growth (+28% YoY), substantial margin expansion (71% gross margin vs 53% prior year), improved adjusted EBITDA (+24% YoY), and robust cash generation (~$58M in Q1) — alongside strategic balance sheet actions and pipeline progress (pediatric label expansion and SG-001 preclinical work). Offsetting these positives were significant near-term headwinds in the standard IG market: BIVIGAM revenue declined sharply (-54% YoY) due to distributor ordering disruption and aggressive competitor discounting (ASP erosion of ~15%–20%), elevated channel inventory and DSOs (~107 days), and withdrawal of longer-term guidance. Overall, the company appears financially resilient and operationally well-positioned, with the performance of ASCENIV and strong cash/margin metrics outweighing the transitory channel and pricing pressures in the standard IG segment.View all ADMA earnings summaries

ADMA Stock 12 Month Forecast

Average Price Target

$23.67

▲(114.96% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","31":"$31","13.75":"$13.75","19.5":"$19.5","25.25":"$25.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.666666666666664,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$23.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,13.75,19.5,25.25,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.52,12.018461538461539,13.516923076923076,15.015384615384615,16.513846153846153,18.012307692307694,19.51076923076923,21.00923076923077,22.50769230769231,24.006153846153847,25.504615384615384,27.00307692307692,28.501538461538463,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.52,11.531282051282052,12.542564102564102,13.553846153846152,14.565128205128204,15.576410256410256,16.587692307692308,17.598974358974356,18.610256410256408,19.62153846153846,20.63282051282051,21.64410256410256,22.655384615384612,{"y":23.666666666666664,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.52,11.249230769230769,11.978461538461538,12.707692307692307,13.436923076923076,14.166153846153845,14.895384615384614,15.624615384615385,16.353846153846153,17.083076923076923,17.81230769230769,18.54153846153846,19.270769230769233,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":23.27,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.43,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.88,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.05,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.48,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.38,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.24,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.5,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.58,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.11,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.52,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >